Please note that following on from information provided to NICE by the company in September 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3985 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 November 2024 | Discontinued. Please note that following on from information provided to NICE by the company in September 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 06 October 2023 | Suspended. For information, the company have announced that LEAP-006 study did not meet its primary endpoints of overall survival and progression free survival and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 30 March 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer have been revised. It is anticipated that the appraisal will begin in mid-May 2024 when we will write to you about how you can get involved. |
For further information on our processes and methods, please see our CHTE processes and methods manual